Tyrosine-kinase inhibitors (TKIs) have revolutioned the management of iodine-refractory differentiated thyroid cancer (DTC), previously considered as an orphan disease. VEGF pathway is one of the main molecular target of TKIs. We present a preliminary single center study about the possible role of germline VEGF-A and VEGFR-2 SNPs in predicting objective response and clinical outcome in iodinerefractory DTC patients treated with sorafenib.
Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib / Marotta, Vincenzo; Sciammarella, Concetta; Capasso, Mario; Testori, Alessandro; Pivonello, Claudia; Chiofalo Maria, Grazia; Pivonello, Rosario; Pezzullo, Luciano; Botti, Gerardo; Colao, Annamaria; Faggiano, Antongiulio. - In: ENDOCRINE. - ISSN 1355-008X. - (2016), pp. 539-543. [10.1007/s12020-016-1200-6]
Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib
Faggiano Antongiulio
2016
Abstract
Tyrosine-kinase inhibitors (TKIs) have revolutioned the management of iodine-refractory differentiated thyroid cancer (DTC), previously considered as an orphan disease. VEGF pathway is one of the main molecular target of TKIs. We present a preliminary single center study about the possible role of germline VEGF-A and VEGFR-2 SNPs in predicting objective response and clinical outcome in iodinerefractory DTC patients treated with sorafenib.File | Dimensione | Formato | |
---|---|---|---|
Faggiano_Preliminary-data.pdf
accesso aperto
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
583.52 kB
Formato
Adobe PDF
|
583.52 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.